Background: Diabetes mellitus is one of the most chronic metabolic disorders. Since
past few years, our research group had synthesized and evaluated libraries of heterocyclic compounds
against α and β-glucosidase enzymes and found encouraging results. The current study
comprises of evaluation of indane-1,3-dione as antidiabetic agents based on our previously reported
results obtained from closely related moiety isatin and its derivatives.
Objective: A library of twenty three indane-1,3-dione derivatives (1-23) was synthesized and evaluated
for α and β-glucosidase inhibitions. Moreover, in silico docking studies were carried out to investigate
the putative binding mode of selected compounds with the target enzyme.
Methods: The indane-1,3-dione derivatives (1-23) were synthesized by Knoevenagel condensation
of different substituted benzaldehydes with indane-1,3-dione under basic condition. The structures
of synthetic molecules were deduced by using different spectroscopic techniques, including 1H-,
13C-NMR, EI-MS, and CHN analysis. Compounds (1-23) were evaluated for α and β-glucosidase
inhibitions by adopting the literature protocols.
Result: Off twenty three, eleven compounds displayed good to moderate activity against α-
glucosidase enzyme, nonetheless, all compounds exhibited less than 50% inhibition against β-
glucosidase enzyme. Compounds 1, 14, and 23 displayed good activity against α-glucosidase enzyme
with IC50 values of 2.80 ± 0.11, 0.76 ± 0.01, and 2.17 ± 0.18 μM, respectively. The results
have shown that these compounds have selectively inhibited the α-glucosidase enzyme. The in
silico docking studies also supported the above results and showed different types of interactions of
synthetic molecules with the active site of enzyme.
Conclusion: The compounds 1, 14, and 23 have shown good inhibition against α-glucosidase and
may potentially serve as lead for the development of new therapeutic representatives.